Who are Treatment R's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olmesartan/amlodipine + hydrochlorothiazide, if necessary., Atorvastatin, Amlodipine, Perindopril, Amlodipine/Losartan/Chlorthalidone, Nifedipine/Telmisartan, Nicardipine + Verapamil + Nitroglycerin, Amlodipine Besylate / Benazepril Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-r.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Treatment R — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment R (Treatment R) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

marketed Calcium channel blocker L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Treatment R (Treatment R) — Boryung Pharmaceutical Co., Ltd. Treatment R is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Treatment R TARGET	Treatment R	Boryung Pharmaceutical Co., Ltd	marketed	Calcium channel blocker	L-type calcium channels
olmesartan/amlodipine + hydrochlorothiazide, if necessary.	olmesartan/amlodipine + hydrochlorothiazide, if necessary.	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC)
Atorvastatin, Amlodipine, Perindopril	Atorvastatin, Amlodipine, Perindopril	Charles University, Czech Republic	marketed	Fixed-dose combination: statin, calcium channel blocker, ACE inhibitor	HMG-CoA reductase (atorvastatin); L-type calcium channels (amlodipine); Angiotensin-converting enzyme (perindopril)
Amlodipine/Losartan/Chlorthalidone	Amlodipine/Losartan/Chlorthalidone	Hanmi Pharmaceutical Company Limited	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic)	L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter
Nifedipine/Telmisartan	Nifedipine/Telmisartan	Bayer	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type calcium channels; AT1 angiotensin II receptor
Nicardipine + Verapamil + Nitroglycerin	Nicardipine + Verapamil + Nitroglycerin	Peng Roc Chen, MD	marketed	Combination antihypertensive/antianginal (calcium channel blockers + nitrate)	L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin)
Amlodipine Besylate / Benazepril Hydrochloride	Amlodipine Besylate / Benazepril Hydrochloride	Dr. Reddy's Laboratories Limited	marketed	Calcium channel blocker / ACE inhibitor combination	L-type calcium channels; Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Ain Shams University · 1 drug in this class
Bioprojet · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Handok Inc. · 1 drug in this class
Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
Hospital de Clinicas de Porto Alegre · 1 drug in this class
Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment R — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-r. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing